Cancer cachexia therapy: A key weapon in the fight against cancer

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 14, Issue 3, 2011, Pages 268-273

  Coss, Christopher C ^a   Bohl, Casey E ^a   Dalton, James T ^a  

^a GTx Inc   (United States)

Author keywords

cancer adjuvant care; cancer cachexia; cancer wasting

Indexed keywords

ANABOLIC AGENT; APPETITE STIMULANT; GROWTH FACTOR; MONOCLONAL ANTIBODY; OXANDROLONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR;

APPETITE; ARTICLE; BODY COMPOSITION; CACHEXIA; CANCER CACHEXIA; CANCER SURVIVAL; CLINICAL EVALUATION; DIET THERAPY; HUMAN; LUNG CANCER; PATIENT CARE; QUALITY OF LIFE; WASTING SYNDROME; WEIGHT REDUCTION;

ACTIVITIES OF DAILY LIVING; ANABOLIC AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APPETITE; BODY COMPOSITION; CACHEXIA; HUMANS; NEOPLASMS; WEIGHT LOSS;

EID: 79955031815     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3283455e21     Document Type: Article

References (57)

1. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793-799
2. Blum D, Omlin A, Fearon K, et al. Evolving classification systems for cancer cachexia: ready for clinical practice? Support Care Cancer 2010; 18:273-279.
3. Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and precachexia: joint document elaborated by Special Interest Groups (SIG) 'cachexia-anorexia in chronic wasting diseases' and 'nutrition in geriatrics'. Clin Nutr 2010; 29:154-159.
4. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11:400-407.
5. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83:735-743. (Pubitemid 44713134)
6. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89:381-410.
7. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15:2920-2926.
8. Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004; 90:1905-1911. (Pubitemid 38746329)
9. Stepp L, Pakiz TS. Anorexia and cachexia in advanced cancer. Nurs Clin North Am 2001; 36:735-744; vii.
10. Bennani-Baiti N, Walsh D. What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb 2009; 39:257-262.
11. Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr 2006; 26:435-461.
12. Tisdale MJ. Cancer cachexia. Langenbecks Arch Surg 2004; 389:299-305. (Pubitemid 39128544)
13. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371:771-783.
14. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 2011; 62:265-279.
15. Baracos VE. Management of muscle wasting in cancer-associated cachexia: understanding gained from experimental studies. Cancer 2001; 92:1669-1677. (Pubitemid 32939173)
16. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999; 97:215-223. (Pubitemid 29396627)
17. MacDonald N, Easson AM, Mazurak VC, et al. Understanding and managing cancer cachexia. J Am Coll Surg 2003; 197:143-161. (Pubitemid 36759189)
18. Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Am J Clin Nutr 1997; 66:683-706
19. Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 2010; 91:1143S-1147S.
20. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004; 64:725-750. (Pubitemid 38471373)
21. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13:3264-3268. (Pubitemid 46944911)
22. Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 1997; 315:1219-1222. (Pubitemid 27478219)
23. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003; 237:384-389. (Pubitemid 38176454)
24. Kotler DP. Cachexia. Ann Intern Med 2000; 133:622-634.
25. Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol 2000; 1:138-147.
26. Bozzetti F, Gavazzi C, Mariani L, Crippa F. Artificial nutrition in cancer patients: which route, what composition? World J Surg 1999; 23:577-583. (Pubitemid 29215630)
27. Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer 2009; 18:1-9.
28. Muscaritoli M, Bossola M, Aversa Z, et al. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006; 42:31-41. (Pubitemid 41814530)
29. Behl D, Jatoi A. Pharmacological options for advanced cancer patients with loss of appetite and weight. Expert Opin Pharmacother 2007; 8:1085-1090. (Pubitemid 46929301)
30. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17:3299-3306. (Pubitemid 29470666)
31. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001; 61:499-514. (Pubitemid 32368064)
32. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20:567-573. (Pubitemid 34072541)
33. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24:3394-3400. (Pubitemid 46638895)
34. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38:1-20. (Pubitemid 16077323)
35. Argiles JM, Lopez-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1998; 1:245-251. (Pubitemid 128539449)
36. Davis TW, Zweifel BS, O'Neal JM, et al. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 2004; 308:929-934. (Pubitemid 38263967)
37. Mantovani G, Maccio A, Madeddu C, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med 2010; 88:85-92.
38. Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003; 17:677-682. (Pubitemid 36418891)
39. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54:540-545. (Pubitemid 40403032)
40. Gelato M, McNurlan M, Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther 2007; 29:2269-2288. (Pubitemid 350298124)
41. Estivariz CF, Ziegler TR. Nutrition and the insulin-like growth factor system. Endocrine 1997; 7:65-71. (Pubitemid 127483089)
42. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebocontrolled trial. Serostim Study Group. Ann Intern Med 1996; 125:873-882.
43. Rodriguez-Arnao J, Jabbar A, Fulcher K, et al. Effects of growth hormone replacement on physical performance and body composition in GH deficient adults. Clin Endocrinol (Oxf) 1999; 51:53-60. (Pubitemid 29339535)
44. Birzniece V, Nelson AE, Ho KK. Growth hormone administration: is it safe and effective for athletic performance. Endocrinol Metab Clin North Am 2010; 39:11-23; vii.
45. Binnerts A, Uitterlinden P, Hofland LJ, et al. The in vitro and in vivo effects of human growth hormone administration on tumor growth of rats bearing a transplantable rat pituitary tumor (7315b). Eur J Cancer 1990; 26:269-276. (Pubitemid 20149152)
46. Kamiji MM, Inui A. The role of ghrelin and ghrelin analogues in wasting disease. Curr Opin Clin Nutr Metab Care 2008; 11:443-451.
47. DeBoer MD. Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 2008; 24:806-814.
48. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008; 98:300-308. (Pubitemid 351161246)
49. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007; 12:594-600. (Pubitemid 350012123)
50. Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 2009; 19:267-273.
51. Bhasin S. The brave new world of function-promoting anabolic therapies: testosterone and frailty. J Clin Endocrinol Metab 2010; 95:509-511.
52. Neischlag E, Behre HM, Nieschlag S. Testosterone: action, deficiency, substitution. Cambridge, UK: Cambridge University Press; 2004.
53. Lesser G, Case D, Ottery F, et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. J Clin Oncol 2008; 26(Suppl 15):9513
54. Mohler ML, Bohl CE, Jones A, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem2009; 52:3597-3617.
55. Bhasin S, CalofOM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2:146-159.
56. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 2007; 12:241-248.
57. Evans W, Smith M, Morley J, et al. Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: implications for cancer cachexia patients. J Clin Oncol 2007; 25(Suppl 18):9119.